PHE’s Shafrin Defines Precision Medicine for US News & World Report
In a new commentary for US News & World Report, Precision Health Economics’ senior research economist Jason Shafrin defines and elaborates on the field of precision medicine. (more…)
Precision’s Leavitt in PM360: What to Do If Your Drug Is on the New Formulary Exclusion List
In a new article on PM360, Precision for Value executive vice president Bruce Leavitt provides step-by-step guidance for drug makers who find their product on one of the recently released formulary exclusion lists. (more…)
Schafer Discusses Oncology Value Frameworks With Managed Healthcare Executive
In the latest edition of Managed Healthcare Executive, Jeremy Schafer, Precision for Value senior vice president, director of payer access solutions, discusses value in oncology and explains how payers are using value frameworks in their drug management process. (more…)
Precision’s Messerschmidt Talks Immunotherapy with ASCO Post
Precision Oncology Chief Medical Officer Gerald Messerschmidt sits down to talk with ASCO Post‘s Ronald Piana regarding the future of immunotherapy. (more…)
Jena Discusses New PHE Preeclampsia Study With Orlando Sentinel
PHE Scientific Advisor Anupam Jena, coauthor of a new study on preeclampsia in the September issue of American Journal of Obstetrics & Gynecology, discussed the study’s findings and the growing economic impact of the condition with the Orlando Sentinel’s Amelia Cheatham. (more…)